LUPIN
|
|
| BOM : 500257 NSE : LUPIN | |
| LT :
Long Term Analysis
Fundamentals : Average
Valuation : Good [Stock is Cheap] Debt : High |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Upward Pledged Shares : None or < 25% |
Jun 24,2022 |
|
Price(EOD): ₹ 629.95
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 28,637.53 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| LUPIN | 3.7% | 4.9% | -45.8% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.4% | -8.5% | 23.8% |
| DIVIS LABORATORIES | 4.3% | 6.7% | -12.6% |
| DR REDDYS LABORATORIES | 3.8% | 0% | -18.7% |
| CIPLA | 0.8% | -3.2% | -2.4% |
| GLAND PHARMA | 2.4% | -7.3% | -17.9% |
| PIRAMAL ENTERPRISES | 3.9% | -11% | -33.4% |
| CADILA HEALTHCARE | 5.7% | -5.1% | -45.1% |
| TORRENT PHARMACEUTICALS | 4.1% | -0.9% | -2.5% |
FUNDAMENTAL ANALYSIS OF LUPIN
[ Q(TTM): Mar2022, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF LUPIN
[As on : Jun 24,2022
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
23.5
P/E Calculated based on EPS of 26.81
[ Mar2021 - Consolidated Results ] 2.1
P/B Calculated based on Book Value of 300.06
[ Mar2021 - Consolidated Results ] 1.75
P/S Calculated based on Revenues of 16405.5 Cr
[ TTM - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
-27% -43% -44% |
SHARE PRICE MOMENTUM OF LUPIN
LUPIN vs SENSEX
DEBT OF LUPIN
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2021 2020 2019 Avg_3yrs |
0.02 0 0 0.01 |
0.35 0.51 0.63 0.5 |
|
[Last Annual Data : Mar2021]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF LUPIN
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2022 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF LUPIN
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
-6.68% -38.77% -150.98% -193.23% |
2.64% -68% -116.43% -210.27% |
| QtrlyTrend |
-6 | |
| Latest Qtr: Mar2022 | ||
| Quarterly Result Analysis → | ||
LUPIN related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 3.1% | -1.8% | -13% |
| S&P BSE LARGECAP | 2.6% | -2.2% | -0.4% |
| S&P BSE CARBONEX | 2.6% | -2.1% | -0.2% |
| S&P BSE 200 | 2.6% | -1.9% | -0.7% |
| S&P BSE LARGE MIDCAP | 2.6% | -1.9% | -0.7% |
| S&P BSE 100 | 2.6% | -2.1% | -0.4% |
| S&P BSE 250 LARGEMIDCAP | 2.5% | -2% | -0.8% |
| S&P BSE 500 | 2.5% | -2% | -1% |
| S&P BSE ALLCAP | 2.5% | -2% | -0.8% |
| S&P BSE SENSEX NEXT 50 | 2.2% | -2.7% | -1.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY HEALTHCARE | 3.3% | -1.7% | -11.6% |
| NIFTY PHARMA | 3.2% | -2.9% | -13.5% |
| NIFTY GROWTH SECTOR 15 | 2.9% | -0.1% | 2.4% |
| NIFTY 100 EQUAL WEIGHT | 2.9% | -1.6% | -2.9% |
| NIFTY 100 | 2.7% | -2% | -0.8% |
| NIFTY NEXT 50 | 2.7% | -1.8% | -5.3% |
| NIFTY 200 | 2.6% | -2% | -0.9% |
| NIFTY 500 | 2.5% | -2% | -1% |
| NIFTY LARGE MIDCAP 250 | 2.4% | -1.7% | -0.8% |
| NIFTY500 MULTICAP 50:25:25 | 2.3% | -2% | -1.3% |
You may also like the below Video Courses
FAQ about LUPIN
Is LUPIN good for long term investment?
As on Jun 24,2022, the Fundamentals of LUPIN look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of LUPIN . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is LUPIN UnderValued or OverValued?
As on Jun 24,2022, LUPIN is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of LUPIN ?
As on Jun 24,2022, the Intrinsic Value of LUPIN is Rs. 1,097.34 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 859.03
Fair Value [Median EV / Sales Model] : Rs. 1,097.34
Fair Value [Median Price / Sales Model] : Rs. 1,120.49
Median Fair Value of LUPIN : Rs. 1,097.34
Is LUPIN trading at a Premium or Discount?
As on Jun 24,2022, LUPIN is trading at a Discount of -43% based on the estimates of Median Intrinsic Value!
Check out Annual Financials of Industry Peers
Check out Quarterly Results of Industry Peers
Compare Analytics
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].
